BetaSense

BetaSense

Berlin, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

BetaSense is an early-stage diagnostics company developing a proprietary structural biomarker detection platform called iRS. The technology uses infrared spectroscopy to identify misfolded proteins in biofluids like serum and CSF, demonstrating high diagnostic accuracy (AUC >0.93) for Parkinson's disease. Founded in 2025, the company operates as a CRO lab, collaborates with pharmaceutical partners, and is positioning its platform for clinical diagnostics and drug development support. Its goal is to shift neurodegenerative disease management to pre-symptomatic stages.

Neurodegenerative Diseases

Technology Platform

iRS (immuno-infrared-sensor) platform: An antibody-capture coupled infrared spectroscopy system for label-free detection of disease-specific protein misfolding in biofluids.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

The massive, growing unmet need for early, non-invasive diagnostics in Alzheimer's and Parkinson's disease represents a multi-billion dollar market.
The rise of disease-modifying therapies creates a parallel opportunity for companion diagnostics and clinical trial support services.

Risk Factors

Key risks include the need for large-scale clinical validation and regulatory approval for its diagnostic tests, intense competition from other biomarker technologies, and the challenge of achieving clinical adoption and reimbursement in established healthcare systems.

Competitive Landscape

BetaSense competes in a crowded field of companies developing fluid biomarkers for neurodegeneration, using technologies like SIMOA, mass spectrometry, and other immunoassays. Its differentiation lies in its direct detection of protein structure (misfolding) via infrared spectroscopy, rather than just concentration.